Merck Says Keytruda Cut Progression or Death Risk 43% in Trial
Merck reported a 43% reduction in progression or death risk with Keytruda in a trial for dMMR endometrial cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.